“…9 There have been calls for audits of access to trial results for performance monitoring and comparison, 8 with several recent examples including trials from individual research centres, [10][11][12] all drugs approved in one year, 13 and all trials approved by individual ethics committees. 14 No attempts have, however, been made to systematically compare funder or sponsor policies on transparency. doi: 10.1136/bmj.j3334 | BMJ 2017;358:j3334 | the bmj We identified pharmaceutical companies' policies on access to information about clinical trials and extracted structured data characterising their commitments to register clinical trials, share summary results, share CSRs, and give access to trial data for current and past trials (box 1); and we assessed concordance with ethical and professional guidance.…”